Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing

Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the market ahead of its planned commercial launch later this year.

Archimedes® One was developed to address a central challenge in cell therapy manufacturing: how to scale adherent cell processes without compromising biology or introducing unnecessary complexity.

Today, therapy developers utilizing adherent cell often face a trade-off. Manual 2D systems are labor-intensive, variable, and difficult to scale. Suspension systems offer scalability but frequently require adaptation or modification of sensitive cell types, which can affect product characteristics and comparability. Fixed-bed bioreactors add significant hardware complexity, conditioning vessels, and cost.

Archimedes® One takes a biology-first approach. Instead of forcing adherent cells into suspension or complex matrices, the system enables controlled, perfusion-based adherent culture with integrated process monitoring and automated harvesting. It is compatible with standard biocontrollers for parameters such as pH, dissolved oxygen, and temperature, and does not require conditioning vessels or custom subsystems. The system is designed to combine the familiarity of 2D culture with the control of a bioreactor. Automated and standardized harvesting replaces manual detachment steps, supporting improved reproducibility and a clearer path toward GMP manufacturing and tech transfer between sites.

“Cell therapy manufacturing should not require choosing between biological integrity and industrial scalability,” said Joel Eichmann, Co-Founder of Green Elephant Biotech. “With Archimedes® One, we are introducing a platform that aligns process control with adherent cell biology and reduces operational complexity.”

“As the cell therapy field matures, manufacturing must become more standardized, scalable, and economically viable,” said Felix Wollenhaupt, Co-Founder of Green Elephant Biotech. “Technologies that reduce operational complexity and cost of goods will be critical to making advanced therapies accessible to more patients.”

Alongside the market introduction, Green Elephant Biotech is opening an Early Access Program for selected cell therapy companies and CDMOs. Participants will gain early access to production units, receive dedicated technical support, and have the opportunity to contribute to application data and case studies ahead of the commercial launch.

Companies interested in the Early Access Program can apply via

www.greenelephantbiotech.com/eap

About Green Elephant

Green Elephant Biotech was founded with two driving forces: making advanced therapies more accessible by changing how cells are manufactured and making the life sciences industry more sustainable. Our CellScrew® is a compact 3D-printed system that streamlines adherent cell expansion from research to clinical manufacturing in Cell and Gene Therapies, vaccines, and biologics. With our dynamic adherent bioreactor Archimedes® One, the CellScrew® technology is being extended from manual workflows to automated adherent cell manufacturing. We also apply plant-based bioplastics to conventional labware, including the Green Elephant® microPLAte, a PLA-based 96-well plate. Founded in 2021 as a university spin-off, we operate from Berlin and Giessen with a growing international team